Lucio leprosy with lucio phenomenon.
Leprosy is one of the commonly seen disease in any dermatology outpatient department in our country. India accounts for a major portion of the leprosy patients in the world. All types of the disease, such as tuberculoid, borderline, lepromatous, neuritic and indeterminate leprosy, are seen. However, "lucio leprosy" which is considered a special type of lepromatous leprosy characterised by diffuse involvement has not been reported from India. We are presenting here two cases of "lucio leprosy" with "lucio phenomenon", the lucio phenomenon being a special type of lepra reaction seen in lucio leprosy.
Saoji
V
V
Government Medical College, Nagpur.
Salodkar
A
A
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001132:Arm / Q000002:abnormalities; D002991:Clofazimine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D005145:Face / Q000002:abnormalities*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007866:Leg / Q000002:abnormalities; D007917:Leprostatic Agents / Q000627:therapeutic use; D015440:Leprosy, Lepromatous / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D009666:Nose / Q000002:abnormalities*; D011239:Prednisolone / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D012883:Skin Ulcer / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D007917:Leprostatic Agents; D003622:Dapsone; D011239:Prednisolone; D002991:Clofazimine; D012293:Rifampin